Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Ronny Drapkin et al.|Nature reviews. Cancer|2015Cited by 1.4k
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Anne Floquet et al.|The Lancet Oncology|2021Cited by 412
Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesisEwa M. Michalak, Clare L. Scott|Cell Death and Differentiation|2009Cited by 162
Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenograftsMonique Topp, Clare L. Scott, Lynne Hartley et al.|Molecular Oncology|2014Cited by 141